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Background: Clostridium difficile is an important cause of infectious colitis among hos-
pitalized patients across the globe. The pathogenic potential of C. difficile in producing 
significant morbidity and mortality is mainly due to production of toxins A and B. The 
outbreaks of C. difficile infection (CDI) are due to changes in the genetic sequences of 
the organism. There is hardly any molecular study reported on the prevalent types of 
C. difficile strains in India. Toxinotyping and sequencing of locally circulating C. difficile 
isolates from patients presenting to our tertiary care center of North India were done.
Materials and methods: C. difficile strains (n = 174) isolated from 1,110 fecal samples 
from patients with suspected CDI were subjected to toxinotyping and partial sequencing 
of tcdA and tcdB genes. Comparison of nucleotide sequences with reference C. diffi-
cile 630 strain using BLAST was made and translated into corresponding amino acid 
sequences by ExPASy.
results and discussion: Of 174 C. difficile isolates, 121 were toxigenic, belonging to 
toxinotype 0 (n = 76) and VIII (n = 45). Partial sequencing of toxin genes using bioin-
formatics approaches revealed changes in toxin A sequences of five (50%) C. difficile 
isolates, but the translated nucleotide sequences showed substitution in only three of 
them. No variation was seen in the toxin B nucleotide sequences. Interstrain variations 
were found in the clinical C. difficile isolates in our region.
conclusion: PCR amplified toxigenic genes followed by sequencing can help to identify 
genetic changes and pathogenicity of varied collection of C. difficile isolates.
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inTrODUcTiOn
Clostridium difficile, an anaerobic spore-bearing organism, is an important cause of infectious 
colitis among in-patients across the globe and particularly so in North America and Europe (1). The 
increase in the morbidity and mortality due to C. difficile is worrisome. Clinically significant strains 
of C. difficile are capable of producing two major toxins: toxin A (TcdA) and toxin B (TcdB), which 
TaBle 1 | Primers used for identification of toxigenic genes (fragments).
Target gene Primers sequence 5′3′ annealing temperature (°c) amplicon size (bp)
A1 Fw GGAGGTTTTTATGCTTTAATATCTAAAGA 57 3,100
Rv CCCTCTGTTATTGTAGGTAGTACATTTA
A2 Fw TAAATGTACTACCTACAATAACAGAGGG 57 2,000
Rv CTTGTATATAAATCAGGTGCTATCAATA
A3 Fw TATTGATAGCACCTGATTTATATACAAG 47 3,100
Rv TTATCAAACATATATTTTAGCCATATATC
B1 Fw AGAAAATTTTATGAGTTTAGTTAATAGAAA 57 3,100
Rv CAGATAATGTAGGAAGTAAGTCTATAG
B2 Fw ATAGACTTACTTCCTACATTATCTGAA 47 2,000
Rv CATCTGTATAAATATTTGGTGAAATTAC
B3 Fw ATTTCACCAAATATTTATACAGATG 47 2,000
Rv ATTTAACATATTTTTATCTATTCA
2
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are encoded by tcdA and tcdB genes, respectively, present on the 
19.6 kb pathogenicity locus (PaLoC) of C. difficile chromosome 
(2, 3). From 2003 onward, several outbreaks have been reported 
due to NAP1/BI/027, a high-level toxin-producing C. difficile 
strain isolated from North America (3), Europe (4), and Japan 
(5). NAP1/BI/027 is more prolific in sporulation than its non-
hypervirulent counterpart and produces more amount of toxins 
than the historical strain (4). The C. difficile infection (CDI) 
outbreaks are due to changes in the genetic sequences called the 
“genetic switch” (6). Comparison of whole genome sequencing 
of historical strain with the hypervirulent strain showed that 
C. difficile had acquired genes that enabled it to survive better 
in the environment (7). This hypervirulent strain is also linked 
with a more serious course of infection, higher relapse rate, and 
complications leading to higher mortality (8).
Apart from the NAP1/BI/027, several other C. difficile strains 
have been reported from various countries (1). Also, strains that 
produce only toxin B but not toxin A have appeared in Asia (9) 
and Latin America (10). The occurrence of different C. difficile 
strains circulating globally has led to the advancement of meth-
ods for a better insight into the pathogenicity of various strains 
in the etiology of nosocomial outbreaks and to provide a better 
follow-up of the epidemiology of the disease (11).
There is hardly any molecular study reported on the prevalent 
types of C. difficile strains in India (9). In the wake of several 
global outbreaks, the locally circulating strain types of C. difficile 




The study protocol was approved by the Institute Ethics 
Committee and was carried out in accordance with the recom-
mendations of ICMR Ethical Guidelines for Biomedical Research 
in India, New Delhi, with written informed consent from all 
subjects in accordance with the Declaration of Helsinki. A total of 
1,110 (M:F = 1.8:1; age range >2–95 years) consecutive hospital-
ized patients who developed diarrhea after ≥72 h of admission 
in various wards and suspected of CDI by the clinicians were 
enrolled for the investigation (12). Patients with incomplete 
data, pregnant women, and children <2 years were excluded (12). 
Apart from Chandigarh, our tertiary care referral hospital accom-
modates patients from various regions of North India inclusive of 
Jammu and Kashmir, Punjab, Haryana, Himachal Pradesh, Uttar 
Pradesh, and Rajasthan as reported earlier (12). The patients were 
clinically evaluated for CDI symptoms inclusive of fever and pain 
abdomen by the clinicians. CDI was diagnosed/suspected by 
the clinicians based on clinical signs and symptoms (diarrhea/
fever/abdominal pain/antibiotic exposure) and/or endoscopic 
evaluation.
A total of 174 C. difficile isolates were obtained after culture 
of single fecal sample per patient from 1,110 patients. After 
phenotypic and genotypic confirmation (12) and amplification 
of tcdA and tcdB genes (13), the C. difficile isolates were subjected 
to toxinotyping and partial sequencing.
Toxinotyping
Toxigenic C. difficile isolates were identified for changes in 
PaLoc region by toxinotyping method (14). The entire tcdA and 
tcdB genes were amplified using six different overlapping PCRs 
(Table 1). In brief, isolation of DNA was carried out by the phe-
nol–chloroform technique, and PCR amplification was carried 
out in a Mastercycler (Eppendorf, Germany). PCRs were done 
in 50 μl volume containing DNA (300 ng), each paired primer 
(15 pmol), a concentration of each deoxynucleoside triphosphate 
(200 μM), and Taq polymerase (2.5 U). Two-step PCR programs 
used included initial denaturation at 93°C for 3 min and annealing 
and extension for 8 min at 56°C (fragments A1 and A2) or at 47°C 
(fragments A3, B1, B2, B3), followed by denaturation at 93°C for 
4 s. Agarose (1.5%) was used to visualize the size differences in the 
amplified fragments, which were further subjected to digestion 
with different restriction enzymes to identify polymorphism.
Partial sequencing of tcda and tcdB 
genes
Partial sequencing of 10 representative isolates, each of amplified 
tcdA and tcdB genes were performed to identify the nucleotide 
FigUre 1 | Pcr amplified fragment B3 of toxin B gene (2,000 bp).
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changes in them. The sequencing of fragments was carried out 
by Di-deoxy Sanger method. Comparison was made with known 
sequences of the tcdA and tcdB genes of reference strain C. dif-
ficile 630 (ribotype 012; toxinotype 0) using basic local alignment 
search tool (BLAST 2.2.29+) software accessed online from the 
National Center of Biotechnology Information (15). Nucleotide 
sequences alignment was done by multiple sequence comparison 
using log-expectation software and translated into amino acids 




Of 174 C. difficile isolates, 121 (69.5%) possessed either the tcdA 
or the tcdB gene or both. All of the toxigenic isolates were checked 
for the presence of fragments of toxins A1–A3 and B1–B3. 
Amplified toxin B3 fragment is shown in Figure 1. The fragments 
of toxins A and B after digestion with HindIII and RsaI showed 
different polymorphic restriction patterns. Toxin B3 fragment 
digested with restriction enzymes is shown in Figure 2. Of the 
121 toxigenic isolates, 76 (62.8%) belonged to toxinotype 0 and 
45 (37.2%) to toxinotype VIII. Both tcdA and tcdB genes were 
present in 65 isolates of toxinotype 0. Four isolates of toxinotype 
0 and nine of toxinotype VIII showed presence of only tcdA 
gene, whereas 36 isolates of toxinotype VIII had only tcdB gene. 
Relation of toxigenic genes to toxinotypes is depicted in Table 2.
sequences of Toxin a and B genes
In all the representative isolates—10 each for toxin A and toxin 
B genes—the expected 624 and 591 bp bands of tcdA and tcdB, 
respectively, were found. The sequence of tcdA and tcdB genes of 
reference strain aligned with tcdA and tcdB genes of the isolates 
showed substitutions in toxin A sequences of five C. difficile 
isolates (Figure  3). In three isolates, cytosine was changed to 
thymine, and in another two isolates, adenine was replaced with 
guanine in tcdA gene (Table 3). In toxin B, there was no variation 
in the nucleotide sequences of any of the isolate. The annotated 
sequences of these isolates have been deposited with the National 
Center of Biotechnology, USA (Accession nos. KP182924-28).
DiscUssiOn
The studies on CDI throughout Asia (9) and particularly India 
are limited due to the difficulty in culturing the pathogen as well 
as lack of funding. The current known burden of CDI in the local 
region is 17.5% (16). As reported earlier (13), toxigenic isolates 
were highly associated with cancers (77.3%), followed by surgery 
(75.0%) and gastrointestinal diseases (70.5%).
Due to the changes in the gene sequence of the toxin, the 
protein structure may also change leading to non-recognition by 
specific antibodies used in the diagnostic assays, and thus, cases 
of CDI may be missed. PCR amplification of toxigenic genes 
can help identify pathogenicity of C. difficile isolates because 
of its high sensitivity (17). As reported earlier (13), of the 121 
toxigenic isolates, 68 (56.2%) possessed both the toxigenic genes 
(tcdA and tcdB), whereas the remaining 53 (43.8%) had one of the 
toxin genes. Only the toxin A (tcdA+tcdB−) gene was found in 13 
(10.7%) and only the toxin B (tcdA−tcdB+) gene in 40 (33.1%) of 
the toxigenic isolates.
In the present study, 62.8% belonged to toxinotype 0 and 
37.2% to toxinotype VIII. Both toxin genes tcdA and tcdB were 







FigUre 2 | Polymorphic restriction patterns of B3 fragment of tcd B 
gene by rFlP.
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present in 85.5% of toxinotype 0. Only tcdA gene was present 
in 5.3% of toxinotype 0 and 20.0% in toxinotype VIII, whereas 
tcdB gene was found in 5.3% of toxinotype 0 and 80.0% of 
toxinotype VIII. The toxinotypes observed in this study were 
similar to those observed from Europe, Asia, and elsewhere (9, 
18–20). There are a few reports for exclusive expression of toxin 
B in Asian isolates. In Shanghai, 33.3% of the isolated strains 
were A−B+ strains, whereas in Stockholm, there was no A−B+ 
strain (21). In Korea, A−B+ variant was 25.7% (22), whereas 
in Iran, it was much lower than in Korea and Shanghai (23). 
However, there is no Indian study of C. difficile variants avail-
able as of date.
PCR ribotyping compares the patterns of PCR products of the 
16S-23S rRNA intergenic spacer region (24). It has been estab-
lished that toxinotyping and PCR ribotyping correlate well with 
each other (25). The 121 toxigenic C. difficile isolates belonged 
to ribotype 001 (36.8%), ribotype 017 (33.9%), and ribotype 106 
(13.2%) as identified earlier (13), which is in accordance with 
other Asian studies where the most prevalent ribotypes were 
001 and 017 (9). On comparison of ribotyping with the presence 
of toxin genes, our work complements and corroborates these 
studies.
Although the correlation of certain antibiotics with CDI 
is high, all antibiotics, inclusive of vancomycin and metroni-
dazole, can cause CDI. Misuse of antibiotics can lead to the 
potential for spread of resistant organisms that can adversely 
impact the health of patients who are not even exposed to 
them. Detection of resistance pattern to certain antibiotics can 
be useful for epidemiological information and can benefit the 
clinical practitioners in treatment decision making. The drug 
resistance on these 174 isolates was reported earlier (12) where 
C. difficile showed a higher resistance toward clindamycin and 
ciprofloxacin but lower toward metronidazole. While comparing 
the antimicrobial resistance with the ribotypes, we found that 
the antimicrobial resistance rates were significantly different 
between each ribotype (data not shown). Comparison of the 
antibiotic resistogram profile of 121 toxigenic isolates with 
toxinotyping showed that three of the isolates resistant to met-
ronidazole were of toxinotype 0. The most frequent toxinotypes 
resistant to ciprofloxacin were toxinotype 0 (54.2%), toxinotype 
VIII (26.5%), and toxinotype 0 (12.1%). None of the toxigenic 
isolates sensitive to vancomycin and metronidazole belonged to 
toxinotype 0. Forty-two percent of toxigenic isolates resistant 
to clindamycin belonged to toxinotype 0, 36.3% to toxinotype 
VIII, and 15.0% to toxinotype 0 (data not shown). Resistance to 
clindamycin was quite high among toxigenic isolates belonging 
to ribotype 001, toxinotype 0 (42.0%), and among ribotype 009 
(14.5%) of the non-toxigenic isolates. Highest degree of anti-
microbial resistance against ciprofloxacin was seen in ribotype 
001 strain, while in ribotypes 017 and 106, lower resistance was 
found when compared with other ribotypes among toxigenic 
isolates. However, the limitation of this paper is that the anti-
biotic practice influencing the genetic variations in the region 
was not studied.
Several commercial kits available in earlier CDI diagnostic 
kits were designed to detect toxin A alone, and, therefore, A−B+ 
cases were getting missed. ELISA kits that detect only toxin A 
may miss out on toxins from isolates of A−B+ strains and thus 
result in wrong interpretation as the role of toxin B in causing 
CDI is equally important. Of 174 C. difficile isolates, 95 (54.6%) 
expressed toxins by ELISA (Paper under print). As of now, 
sequencing is the best technique to identify and to look for 
any variations in the genetic sequences and will be therefore 
helpful for clinicians to identify the genotype, consequently 
aiding in treatment decisions. In the present study, substitu-
tions were found in tcdA sequences of five isolates but none 
in tcdB gene. Changes in the nucleotide sequence of tcdA gene 
suggest variation in the strains and highlight the usage of C. 
difficile diagnostic methods to detect both toxins A and B (26). 
Horizontal gene transfer could be responsible for the variabil-
ity in the C. difficile DNA fragments amplified and sequenced 
(27). Molecular mechanism accountable for the lack of tcdA− 
strains in 017 toxinotype could be due to sequence variation 
compared with toxigenic strains. Interestingly, NAP1/BI/027 
isolates were not present in our study, and this absence cor-
roborates with the less severe kind of CDI detected in the 
region. However, further study is required at other parts of 
the country.
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cOnclUsiOn
Outbreaks of C. difficile are a global phenomenon, and India has 
also risk of such outbreaks. Therefore, establishment of a global 
surveillance system is required for efficient control of CDI. Also, 
due to the widespread prevalence of ribotype 017 with only tcdB 
gene in Asia including India, the assay for identification of toxin 
B emerges to be more imperative than toxin A for diagnosis of 
CDI. Clinically, this study is useful in considering the ribotype 
and toxinotype trends in relation to antimicrobial resistance of C. 
difficile in India. Genetic variations in C. difficile isolates may alter 
the sensitivity and specificity of diagnostic assays. Moreover, the 
characterization of C. difficile is likely to facilitate and contribute 
to the development of an effective vaccine. Therefore, local data 
of the toxigenicity and genetic variations of C. difficile isolates can 
be very useful.
eThics sTaTeMenT
Full name of the ethics committee: Institute Ethics Committee, 
Post Graduate Institute of Medical Education and Research, 
Chandigarh. Consent procedure: The patients whose fecal sam-
ples were collected were informed about the investigations to be 
conducted on their samples, and informed written consent was 
obtained. No vulnerable populations were involved.
aUThOr cOnTriBUTiOns
CV conceived and designed the work, monitored the experi-
ments, and supervised the final draft. RK provided the patients 
for clinical specimens and helped in drafting the paper. MS car-
ried out the experiments, analyzed the data, performed literature 
search, and wrote the preliminary draft. SM approved the design, 
supervised the technical part of the experiments conducted, and 
approved the final draft.
acKnOWleDgMenTs
The authors thank Mr. Prashant Kapoor and Mr. Gurinder Singh 
Cheema for technical assistance.
FUnDing
This project was funded by Council of Scientific and Industrial 
Research, New Delhi, India [grant no. 27(259)/12].
TaBle 3 | Toxin a-positive isolates showing nucleotide substitutions at 
different positions.
isolate no. nucleotide substitution at different positions of tcda gene
A6 C 3338 T C 3500 T C 3774 T T 3716 C
A9 C 3338 T C 3500 T C 3774 T T 3716 C
A13 A 3667 G C 3774 T T 3716 C
A33 C 3500 T C 3774 T T 3716 C
A40 A 3667 G C 3774 T T 3716 C
FigUre 3 | alignment of nucleotides for tcda gene of representative isolates by multiple sequence comparison using log-expectation software.
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